Multiple myeloma (MM) remains an incurable hematological malignancy characterized by clonal proliferation of malignant plasma cells in bone marrow. In the last 20 years, the introduction of autologous stem cell transplantation, followed by proteasome inhibitors and immunomodulatory agents, increased the survival of MM patients by 50%. However, still a high proportion of patients relapse and become refractory, especially, high-risk patients with adverse cytogenetics where these treatment combinations have shown limited benefit. Therefore, novel strategies, such as immunotherapy, have been developed in the last few years to help improve the survival of these patients. Immunotherapy treatments include a high number of different strategies used...
International audienceIntroduction: Immunotherapy has emerged as a major class in the therapeutic ar...
Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent...
Multiple myeloma (MM) is a complex hematologic malignancy characterized by the uncontrolled prolifer...
Multiple myeloma is an incurable disease of malignant plasma cells and an ideal target for modern im...
The treatment of multiple myeloma (MM) has evolved substantially over the past decades, leading to a...
Multiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clona...
Multiple myeloma (MM) is a life-threatening haematological malignancy for which standard therapy is ...
Multiple myeloma (MM) is a currently incurable hematologic cancer. This disease is characterized by ...
: In multiple myeloma impressive outcomes have improved with the introduction of new therapeutic app...
Recurrence of disease due to chemotherapy drug resistance remains a major obstacle to a more success...
Multiple myeloma (MM) is a haematological cancer originating from antibody producing plasma cells. C...
The introduction of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has markedly increa...
Introduction: Multiple myeloma (MM) is characterized by generalized immune suppression and increased...
Immunotherapy is a rapidly developing field of multiple myeloma, a disease which despite the develop...
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has...
International audienceIntroduction: Immunotherapy has emerged as a major class in the therapeutic ar...
Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent...
Multiple myeloma (MM) is a complex hematologic malignancy characterized by the uncontrolled prolifer...
Multiple myeloma is an incurable disease of malignant plasma cells and an ideal target for modern im...
The treatment of multiple myeloma (MM) has evolved substantially over the past decades, leading to a...
Multiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clona...
Multiple myeloma (MM) is a life-threatening haematological malignancy for which standard therapy is ...
Multiple myeloma (MM) is a currently incurable hematologic cancer. This disease is characterized by ...
: In multiple myeloma impressive outcomes have improved with the introduction of new therapeutic app...
Recurrence of disease due to chemotherapy drug resistance remains a major obstacle to a more success...
Multiple myeloma (MM) is a haematological cancer originating from antibody producing plasma cells. C...
The introduction of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has markedly increa...
Introduction: Multiple myeloma (MM) is characterized by generalized immune suppression and increased...
Immunotherapy is a rapidly developing field of multiple myeloma, a disease which despite the develop...
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has...
International audienceIntroduction: Immunotherapy has emerged as a major class in the therapeutic ar...
Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent...
Multiple myeloma (MM) is a complex hematologic malignancy characterized by the uncontrolled prolifer...